Comparison of the SureX® HPV genotyping test with the Digene Hybrid Capture® 2 test in cervical cancer screening
The SureX<sup>®</sup> HPV test exhibited excellent concordance with HC2 in detecting the common 13 HR-HPV types and similar sensitivity for identifying CIN2+ cases. Its broader capability to detect 25 HPV genotypes positions it as a promising option for cervical cancer screening.
Authors
- Peiyao Li (ORCID: https://orcid.org/0000-0001-5145-1678)
- X. Sun (ORCID: https://orcid.org/0009-0006-8296-1869)
- Huifang Xu (ORCID: https://orcid.org/0000-0001-5172-5579)
- Liyang Zheng (ORCID: https://orcid.org/0000-0001-9960-3466)
- Shaokai Zhang (ORCID: https://orcid.org/0000-0002-0154-7126)
- Kunyao Li (ORCID: https://orcid.org/0000-0002-8822-9971)
- Hong Wang (ORCID: https://orcid.org/0000-0002-6140-9462)
- Yin Liu
- Mengjie Li (ORCID: https://orcid.org/0000-0003-2544-2115)
- Peipei Chen (ORCID: https://orcid.org/0000-0003-2507-2185)
- H.K. Sun (ORCID: https://orcid.org/0009-0006-4575-0376)
Institutions
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.3389/fonc.2025.1627935
- Citations
- 1
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.35